1e
19
1
49
2
2
18
1b
1d
18
37
69
1d
2 29
1d
25
Bridget R Durkin, MD, MBE
88
69
Assistant Professor of Clinical Medicine (General Internal Medicine)
28
95
3
5f
Medical Director, Addiction Medicine Consult Team, Hospital of the University of Pennsylvania
7c
Co-Chair, Opioid Task Force, University of Pennsylvania Health System
11
Department: Medicine
4
1
b
1d
46
Contact information
58
4
3
3
3
2
4
b
1f
58
Hospital of the University of Pennsylvania
1a 3400 Spruce Street
3c White Building, 2nd Floor
Philadelphia, PA 19104
26
1a 3400 Spruce Street
3c White Building, 2nd Floor
Philadelphia, PA 19104
2c
Office: 2674020702
30
f
30
13
Education:
21 7 AB 15 (Classics) c
2d Princeton University, 2007.
21 7 MD c
50 Perelman School of Medicine, University of Pennsylvania, 2018.
21 8 MBE 16 (Bioethics) c
50 Perelman School of Medicine, University of Pennsylvania, 2018.
c
3
3
3
3
8d
Permanent link21 7 AB 15 (Classics) c
2d Princeton University, 2007.
21 7 MD c
50 Perelman School of Medicine, University of Pennsylvania, 2018.
21 8 MBE 16 (Bioethics) c
50 Perelman School of Medicine, University of Pennsylvania, 2018.
c
2 29
21
1e
1d
24
5e
16 Medical Ethics
2d Symptom Management in Serious Illness
20 Polysubstance Withdrawal
1e Medetomidine Withdrawal
26 29
27
Description of Clinical Expertise
27 Substance Use Disorder16 Medical Ethics
2d Symptom Management in Serious Illness
20 Polysubstance Withdrawal
1e Medetomidine Withdrawal
26 29
23
f2 Ann A. Soliman, MD, Jennifer M. Olenik, MD, Alana Sagin, MD, MSEd, Bridget Durkin, MD, MBE: Qualitative Study of Preclinical Medical Student Reflections on Required Palliative Care Experience 5f Journal of Pain and Symptom Management 70(3): 287-294, September 2025.
201 Samantha Huo, MD; Kory London, MD; Lauren Murphy, MD; Emily Casey, PharmD; Philip Durney, MD; Maya Arora; Rita McKeever, MD; Abriana Tasillo, MD; Dennis Goodstein, PharmD; Brendan Hart, MD, PhD; Jeanmarie Perrone, MD: "Notes from the Field: Suspected Medetomidine Withdrawal Syndrome Among Fentanyl-Exposed Patients — Philadelphia, Pennsylvania, September 2024–January 2025" Morbidity and Mortality Weekly Report(74), 266-268, May 2025.
11f Bridget Durkin: “Managing the Clinical and Ethical Challenges of Naloxone in Hospitalized Palliative Care Patients.” Annual Assembly of Hospice & Palliative Care. Poster Presentation. Montreal, Canada Mar 2023.
104 Maley JH, et al: “Six-Month Impairment in Cognition, Mental Health, and Physical Function Following COVID-19-Associated Respiratory Failure.” Critical Care Exploration 4(4), Mar 2022.
2c
7
1d
1f
Selected Publications
143 Tyler G. Boyce, Ashish P. Thakrar, MD, MS, Bridget R. Durkin, MD, MBE, Emily R. Casey, PharmD, BCPMP, Lin Xu, MS, Margaret Lowenstein, MD,MPhil, MSHP: "Trends in Hospital and Intensive Care Unit Admissions for Medetomidine Withdrawal" in review 2026.f2 Ann A. Soliman, MD, Jennifer M. Olenik, MD, Alana Sagin, MD, MSEd, Bridget Durkin, MD, MBE: Qualitative Study of Preclinical Medical Student Reflections on Required Palliative Care Experience 5f Journal of Pain and Symptom Management 70(3): 287-294, September 2025.
201 Samantha Huo, MD; Kory London, MD; Lauren Murphy, MD; Emily Casey, PharmD; Philip Durney, MD; Maya Arora; Rita McKeever, MD; Abriana Tasillo, MD; Dennis Goodstein, PharmD; Brendan Hart, MD, PhD; Jeanmarie Perrone, MD: "Notes from the Field: Suspected Medetomidine Withdrawal Syndrome Among Fentanyl-Exposed Patients — Philadelphia, Pennsylvania, September 2024–January 2025" Morbidity and Mortality Weekly Report(74), 266-268, May 2025.
11f Bridget Durkin: “Managing the Clinical and Ethical Challenges of Naloxone in Hospitalized Palliative Care Patients.” Annual Assembly of Hospice & Palliative Care. Poster Presentation. Montreal, Canada Mar 2023.
104 Maley JH, et al: “Six-Month Impairment in Cognition, Mental Health, and Physical Function Following COVID-19-Associated Respiratory Failure.” Critical Care Exploration 4(4), Mar 2022.
2c